SHR-1210
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Nasopharyngeal Carcinoma
Conditions
Nasopharyngeal Carcinoma
Trial Timeline
Aug 14, 2018 → Dec 30, 2021
NCT ID
NCT03558191About SHR-1210
SHR-1210 is a phase 2 stage product being developed by Jiangsu Hengrui Medicine for Nasopharyngeal Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT03558191. Target conditions include Nasopharyngeal Carcinoma.
What happened to similar drugs?
0 of 13 similar drugs in Nasopharyngeal Carcinoma were approved
Approved (0) Terminated (0) Active (13)
🔄PD-1 blocking antibody + Gemcitabine + Cisplatin (80 mg/m2) + Cisplatin (100 mg/m2) + CapecitabineSun PharmaceuticalPhase 3
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (9)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03558191 | Phase 2 | Completed |
| NCT03557411 | Phase 2 | UNKNOWN |
| NCT03363555 | Phase 2 | UNKNOWN |
| NCT03222440 | Pre-clinical | Completed |
| NCT03155425 | Phase 2 | Completed |
| NCT03085069 | Phase 2 | UNKNOWN |
| NCT02989922 | Phase 2 | Completed |
| NCT02738489 | Phase 1 | Completed |
| NCT02721589 | Phase 1 | Completed |
Competing Products
20 competing products in Nasopharyngeal Carcinoma